Safety and long-term immunological effects of CryJ2-LAMP plasmid vaccine in Japanese red cedar atopic subjects: A phase I study

References

• Yamada T, Saito H, Fujieda S. Present state of Japanese cedar pollinosis: The national affliction. J Allergy Clin Immunol 2014; 133:632-9 e5; PMID: 24361081; https://doi.org/10.1016/j.jaci.2013.11.002
   PubMed Web of Science ®Google Scholar
• Sone T, Komiyama N, Shimizu K, Kusakabe T, Morikubo K, Kino K. Cloning and sequencing of cDNA coding for Cry j I, a major allergen of Japanese cedar pollen. Biochem Biophys Res Commun 1994; 199:619-25; PMID: 8135802; https://doi.org/10.1006/bbrc.1994.1273
   PubMed Web of Science ®Google Scholar
• Yasueda H, Yui Y, Shimizu T, Shida T. Isolation and partial characterization of the major allergen from Japanese cedar (Cryptomeria japonica) pollen. J Allergy Clin Immunol 1983; 71:77-86; PMID: 6822692; https://doi.org/10.1016/0091-6749(83)90550-X
   PubMed Web of Science ®Google Scholar
• Sakaguchi M, Inouye S, Taniai M, Ando S, Usui M, Matuhasi T. Identification of the second major allergen of Japanese cedar pollen. Allergy 1990; 45:309-12; PMID: 2382797; https://doi.org/10.1111/j.1398-9995.1990.tb00501.x
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Nigi H, Sakaguchi M, Inouye S, Imaoka K, Miyazawa H, Taniguchi Y, Kurimoto M, Yasueda H, Ogawa T. Sensitivity to two major allergens (Cry j I and Cry j II) in patients with Japanese cedar (Cryptomeria japonica) pollinosis. Clin Exp Allergy 1995; 25:848-52; PMID: 8564723; https://doi.org/10.1111/j.1365-2222.1995.tb00027.x
   PubMed Web of Science ®Google Scholar
• Sugimura K, Hashiguchi S, Takahashi Y, Hino K, Taniguchi Y, Kurimoto M, Fukuda K, Ohyama M, Yamada G. Th1/Th2 response profiles to the major allergens Cry j 1 and Cry j 2 of Japanese cedar pollen. Allergy 1996; 51:732-40; PMID: 8905002
   PubMed Web of Science ®Google Scholar
• Sone T, Dairiki K, Morikubo K, Shimizu K, Tsunoo H, Mori T, Kino K. Identification of human T cell epitopes in Japanese cypress pollen allergen, Cha o 1, elucidates the intrinsic mechanism of cross-allergenicity between Cha o 1 and Cry j 1, the major allergen of Japanese cedar pollen, at the T cell level. Clin Exp Allergy 2005; 35:664-71; PMID: 15898991; https://doi.org/10.1111/j.1365-2222.2005.02221.x
   PubMed Web of Science ®Google Scholar
• Sone T, Dairiki K, Morikubo K, Shimizu K, Tsunoo H, Mori T, Kino K. Recognition of T cell epitopes unique to Cha o 2, the major allergen in Japanese cypress pollen, in allergic patients cross-reactive to Japanese cedar and Japanese cypress pollen. Allergol Int 2009; 58:237-45; PMID: 19307778; https://doi.org/10.2332/allergolint.08-OA-0027
   PubMedGoogle Scholar
• Okamoto Y, Horiguchi S, Yamamoto H, Yonekura S, Hanazawa T. Present situation of cedar pollinosis in Japan and its immune responses. Allergol Int 2009; 58:155-62; PMID: 19307773; https://doi.org/10.2332/allergolint.08-RAI-0074
   PubMedGoogle Scholar
• Aceituno E, Del Pozo V, Minguez A, Arrieta I, Cortegano I, Cardaba B, Gallardo S, Rojo M, Palomino P, Lahoz C. Molecular cloning of major allergen from Cupressus arizonica pollen: Cup a 1. Clin Exp Allergy 2000; 30:1750-8; PMID: 11122214; https://doi.org/10.1046/j.1365-2222.2000.00949.x
   PubMed Web of Science ®Google Scholar
• Midoro-Horiuti T, Goldblum RM, Kurosky A, Wood TG, Schein CH, Brooks EG. Molecular cloning of the mountain cedar (Juniperus ashei) pollen major allergen, Jun a 1. J Allergy Clin Immunol 1999; 104:613-7; PMID: 10482836; https://doi.org/10.1016/S0091-6749(99)70332-5
   PubMed Web of Science ®Google Scholar
• Ito H, Nishimura J, Suzuki M, Mamiya S, Sato K, Takagi I, Baba S. Specific IgE to Japanese cypress (Chamaecyparis obtusa) in patients with nasal allergy. Ann Allergy Asthma Immunol 1995; 74:299-303; PMID: 7719888
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Miyahara M, Shimizu K, Kino K, Tsunoo H. Purification, identification, and cDNA cloning of Jun a 2, the second major allergen of mountain cedar pollen. Biochem Biophys Res Commun 2000; 275:195-202; PMID: 10944464; https://doi.org/10.1006/bbrc.2000.3273
   PubMed Web of Science ®Google Scholar
• Ramirez DA. The natural history of mountain cedar pollinosis. J Allergy Clin Immunol 1984; 73:88-93; PMID: 6537956; https://doi.org/10.1016/0091-6749(84)90489-5
   PubMed Web of Science ®Google Scholar
• Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356:152-4; PMID: 1545867; https://doi.org/10.1038/356152a0
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259:1745-9; PMID: 8456302; https://doi.org/10.1126/science.8456302
   PubMed Web of Science ®Google Scholar
• Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev 2011; 239:62-84; PMID: 21198665; https://doi.org/10.1111/j.1600-065X.2010.00980.x
   PubMed Web of Science ®Google Scholar
• Kapsenberg ML, Jansen HM, Bos JD, Wierenga EA. Role of type 1 and type 2 T helper cells in allergic diseases. Curr Opin Immunol 1992; 4:788-93; PMID: 1466803; https://doi.org/10.1016/0952-7915(92)90063-K
   PubMed Web of Science ®Google Scholar
• Hsu CH, Chua KY, Tao MH, Lai YL, Wu HD, Huang SK, Hsieh KH. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat Med 1996; 2:540-4; PMID: 8616712; https://doi.org/10.1038/nm0596-540
   PubMed Web of Science ®Google Scholar
• Tan LK, Huang CH, Kuo IC, Liew LM, Chua KY. Intramuscular immunization with DNA construct containing Der p 2 and signal peptide sequences primed strong IgE production. Vaccine 2006; 24:5762-71; PMID: 16740347; https://doi.org/10.1016/j.vaccine.2006.04.064
   PubMed Web of Science ®Google Scholar
• Peng HJ, Su SN, Chang ZN, Chao PL, Kuo SW, Tsai LC. Induction of specific Th1 responses and suppression of IgE antibody formation by vaccination with plasmid DNA encoding Der f 11. Vaccine 2002; 20:1761-8; PMID: 11906763; https://doi.org/10.1016/S0264-410X(02)00029-4
   PubMed Web of Science ®Google Scholar
• Toda M, Sato H, Takebe Y, Taniguchi Y, Saito S, Inouye S, Takemori T, Sakaguchi M. Inhibition of immunoglobulin E response to Japanese cedar pollen allergen (Cry j 1) in mice by DNA immunization: different outcomes dependent on the plasmid DNA inoculation method. Immunology 2000; 99:179-86; PMID: 10692034; https://doi.org/10.1046/j.1365-2567.2000.00935.x
   PubMed Web of Science ®Google Scholar
• Toda M, Kasai M, Hosokawa H, Nakano N, Taniguchi Y, Inouye S, Kaminogawa S, Takemori T, Sakaguchi M. DNA vaccine using invariant chain gene for delivery of CD4+ T cell epitope peptide derived from Japanese cedar pollen allergen inhibits allergen-specific IgE response. Eur J Immunol 2002; 32:1631-9; PMID: 12115646; https://doi.org/10.1002/1521-4141(200206)32:6<1631::AID-IMMU1631>3.0.CO;2-O
   PubMed Web of Science ®Google Scholar
• Rowell JF, Ruff AL, Guarnieri FG, Staveley-O'Carroll K, Lin X, Tang J, August JT, Siliciano RF. Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells. J Immunol 1995; 155:1818-28; PMID: 7636236
   PubMed Web of Science ®Google Scholar
• Ruff AL, Guarnieri FG, Staveley-O'Carroll K, Siliciano RF, August JT. The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway. J Biol Chem 1997; 272:8671-8; PMID: 9079699; https://doi.org/10.1074/jbc.272.13.8671
   PubMed Web of Science ®Google Scholar
• Wu TC, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, Cho KR, August JT, Pardoll DM. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A 1995; 92:11671-5; PMID: 8524826; https://doi.org/10.1073/pnas.92.25.11671
   PubMed Web of Science ®Google Scholar
• Marques ET, Jr., Chikhlikar P, de Arruda LB, Leao IC, Lu Y, Wong J, Chen JS, Byrne B, August JT. HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses. J Biol Chem 2003; 278:37926-36; PMID: 12824194; https://doi.org/10.1074/jbc.M303336200
   PubMed Web of Science ®Google Scholar
• Anwar A, Chandrasekaran A, Ng ML, Marques E, August JT. West Nile premembrane-envelope genetic vaccine encoded as a chimera containing the transmembrane and cytoplasmic domains of a lysosome-associated membrane protein: increased cellular concentration of the transgene product, targeting to the MHC II compartment, and enhanced neutralizing antibody response. Virology 2005; 332:66-77; PMID: 15661141
   PubMed Web of Science ®Google Scholar
• Bonehill A, Heirman C, Tuyaerts S, Michiels A, Breckpot K, Brasseur F, Zhang Y, Van Der Bruggen P, Thielemans K. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 2004; 172:6649-57; PMID: 15153480
   PubMed Web of Science ®Google Scholar
• Su Y, Connolly M, Marketon A, Heiland T. CryJ-LAMP DNA Vaccines for Japanese Red Cedar Allergy Induce Robust Th1-Type Immune Responses in Murine Model. J Immunol Res 2016; 2016:4857869; PMID: 27239481
   PubMed Web of Science ®Google Scholar
• Hirahara K, Saito S, Serizawa N, Sasaki R, Sakaguchi M, Inouye S, Taniguchi Y, Kaminogawa S, Shiraishi A. Oral administration of a dominant T-cell determinant peptide inhibits allergen-specific TH1 and TH2 cell responses in Cry j 2-primed mice. J Allergy Clin Immunol 1998; 102:961-7; PMID: 9847437
   PubMed Web of Science ®Google Scholar
• Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y, Jones TR, Hobart P, Margalith M, Ng J, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282:476-80; PMID: 9774275
   PubMed Web of Science ®Google Scholar
• Chudley L, McCann K, Mander A, Tjelle T, Campos-Perez J, Godeseth R, Creak A, Dobbyn J, Johnson B, Bass P, et al. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. Cancer Immunol Immunother 2012; 61:2161-70; PMID: 22729556
   PubMed Web of Science ®Google Scholar
• Vardas E, Stanescu I, Leinonen M, Ellefsen K, Pantaleo G, Valtavaara M, Ustav M, Reijonen K. Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU((R))-Multi-HIVB, in untreated HIV-1 infected subjects. Vaccine 2012; 30:4046-54; PMID: 22549090
   PubMed Web of Science ®Google Scholar
• Kibuuka H, Berkowitz NM, Millard M, Enama ME, Tindikahwa A, Sekiziyivu AB, Costner P, Sitar S, Glover D, Hu Z, et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet 2015; 385:1545-54; PMID: 25540891
   PubMed Web of Science ®Google Scholar
• Prado N, Canamero M, Villalba M, Rodriguez R, Batanero E. Bystander suppression to unrelated allergen sensitization through intranasal administration of tolerogenic exosomes in mouse. Mol Immunol 2010; 47:2148-51; PMID: 20478618
   PubMed Web of Science ®Google Scholar
• Scholl I, Wiedermann U, Forster-Waldl E, Ganglberger E, Baier K, Boltz-Nitulescu G, Scheiner O, Ebner C, Jensen-Jarolim E. Phage-displayed Bet mim 1, a mimotope of the major birch pollen allergen Bet v 1, induces B cell responses to the natural antigen using bystander T cell help. Clin Exp Allergy 2002; 32:1583-8; PMID: 12569978; https://doi.org/10.1046/j.1365-2222.2002.01527.x
   PubMedGoogle Scholar
• Schabussova I, Ul-Haq O, Hoflehner E, Akgun J, Wagner A, Loupal G, Joachim A, Ruttkowski B, Maizels RM, Wiedermann U. Oesophagostomum dentatum extract modulates T cell-dependent immune responses to bystander antigens and prevents the development of allergy in mice. PLoS One 2013; 8:e67544; PMID: 23844022; https://doi.org/10.1371/journal.pone.0067544
   PubMed Web of Science ®Google Scholar
• Uekusa Y, Inamine A, Yonekura S, Horiguchi S, Fujimura T, Sakurai D, Yamamoto H, Suzuki H, Hanazawa T, Okamoto Y. Immunological parameters associated with the development of allergic rhinitis: a preliminary prospective study. Am J Rhinol Allergy 2012; 26:92-6; PMID: 22487284; https://doi.org/10.2500/ajra.2012.26.3706
   PubMed Web of Science ®Google Scholar
• MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998; 178:92-100; PMID: 9652427; https://doi.org/10.1086/515613
   PubMed Web of Science ®Google Scholar
• Epstein JE, Gorak EJ, Charoenvit Y, Wang R, Freydberg N, Osinowo O, Richie TL, Stoltz EL, Trespalacios F, Nerges J, et al. Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. Hum Gene Ther 2002; 13:1551-60; PMID: 12228010; https://doi.org/10.1089/10430340260201644
   PubMed Web of Science ®Google Scholar
• Richie TL, Charoenvit Y, Wang R, Epstein JE, Hedstrom RC, Kumar S, Luke TC, Freilich DA, Aguiar JC, Sacci JB Jr, et al. Clinical trial in healthy malaria-naive adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA. Hum Vaccin Immunother 2012; 8:1564-84; PMID: 23151451; https://doi.org/10.4161/hv.22129
   PubMed Web of Science ®Google Scholar
• Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, Shen S, Green S, Rothman AL, Ennis FA, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008; 26:3947-57; PMID: 18724414; https://doi.org/10.1016/j.vaccine.2007.12.060
   PubMed Web of Science ®Google Scholar
• Spearman P, Lally MA, Elizaga M, Montefiori D, Tomaras GD, McElrath MJ, Hural J, De Rosa SC, Sato A, Huang Y, et al. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis 2011; 203:1165-73; PMID: 21451004; https://doi.org/10.1093/infdis/jiq175
   PubMed Web of Science ®Google Scholar
• Villarreal DO, Talbott KT, Choo DK, Shedlock DJ, Weiner DB. Synthetic DNA vaccine strategies against persistent viral infections. Expert Rev Vaccines 2013; 12:537-54; PMID: 23659301; https://doi.org/10.1586/erv.13.33
   PubMed Web of Science ®Google Scholar
• Lu S. Immunogenicity of DNA vaccines in humans: it takes two to tango. Hum Vaccin 2008; 4:449-52; PMID: 18443427; https://doi.org/10.4161/hv.4.6.6179
   PubMed Web of Science ®Google Scholar
• Mori T, Yokoyama M, Komiyama N, Okano M, Kino K. Purification, identification, and cDNA cloning of Cha o 2, the second major allergen of Japanese cypress pollen. Biochem Biophys Res Commun 1999; 263:166-71; PMID: 10486272; https://doi.org/10.1006/bbrc.1999.1261
   PubMed Web of Science ®Google Scholar
• Yasueda H, Saito A, Sakaguchi M, Ide T, Saito S, Taniguchi Y, Akiyama K, Inouye S. Identification and characterization of a group 2 conifer pollen allergen from Chamaecyparis obtusa, a homologue of Cry j 2 from Cryptomeria japonica. Clin Exp Allergy 2000; 30:546-50; PMID: 10718852; https://doi.org/10.1046/j.1365-2222.2000.00747.x
   PubMed Web of Science ®Google Scholar